Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells

Dopamine oxidation has been previously demonstrated to cause dysfunction in mitochondrial respiration and membrane permeability, possibly related to covalent modification of critical proteins by the reactive dopamine quinone. However, specific mitochondrial protein targets have not been identified. In this study, we utilized proteomic techniques to identify proteins directly conjugated with (14)C-dopamine from isolated rat brain mitochondria exposed to radiolabeled dopamine quinone (150 microM) and differentiated SH-SY5Y cells treated with (14)C-dopamine (150 microM). We observed a subset of rat brain mitochondrial proteins that were covalently modified by (14)C-dopamine, including chaperonin, ubiquinol-cytochrome c reductase core protein 1, glucose regulated protein 75/mitochondrial HSP70/mortalin, mitofilin, and mitochondrial creatine kinase. We also found the Parkinson's disease associated proteins ubiquitin carboxy-terminal hydrolase L1 and DJ-1 to be covalently modified by dopamine in both brain mitochondrial preparations and SH-SY5Y cells. The susceptibility of the identified proteins to covalent modification by dopamine may carry implications for their role in the vulnerability of dopaminergic neurons in Parkinson's disease pathogenesis.

[1]  D F Hochstrasser,et al.  Toward a clinical molecular scanner for proteome research: parallel protein chemical processing before and during western blot. , 1999, Analytical chemistry.

[2]  G. Cortopassi,et al.  Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. , 2007, Human molecular genetics.

[3]  T. Montine,et al.  The Lipid Peroxidation Product 4‐Hydroxynonenal Inhibits Neurite Outgrowth, Disrupts Neuronal Microtubules, and Modifies Cellular Tubulin , 1999, Journal of neurochemistry.

[4]  A. Schapira,et al.  Mitochondrial involvement in Parkinson’s disease , 2002, Neurochemistry International.

[5]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[6]  Alisdair R Fernie,et al.  Enzymes of Glycolysis Are Functionally Associated with the Mitochondrion in Arabidopsis Cells Article, publication date, and citation information can be found at www.plantcell.org/cgi/doi/10.1105/tpc.012500. , 2003, The Plant Cell Online.

[7]  Rifat Hasan,et al.  Peroxynitrite oxidation of tubulin sulfhydryls inhibits microtubule polymerization. , 2002, Archives of biochemistry and biophysics.

[8]  J. Xie,et al.  The mitochondrial inner membrane protein Mitofilin exists as a complex with SAM50, metaxins 1 and 2, coiled‐coil‐helix coiled‐coil‐helix domain‐containing protein 3 and 6 and DnaJC11 , 2007, FEBS letters.

[9]  P. Jenner,et al.  Oxidative stress in Parkinson's disease , 2003, Annals of neurology.

[10]  I. Ziv,et al.  Prevention of Dopamine-Induced Cell Death by Thiol Antioxidants: Possible Implications for Treatment of Parkinson's Disease , 1996, Experimental Neurology.

[11]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[12]  W. Fischer,et al.  Protein Disulfide Bond Formation in the Cytoplasm during Oxidative Stress* , 2004, Journal of Biological Chemistry.

[13]  K. Vrana,et al.  Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.

[14]  E. Jayatilleke,et al.  Inhibition of brain mitochondrial respiration by dopamine: involvement of H2O2 and hydroxyl radicals but not glutathione–protein–mixed disulfides , 2002, Journal of neurochemistry.

[15]  W. Neupert,et al.  The mitochondrial proteins Ssq1 and Jac1 are required for the assembly of iron sulfur clusters in mitochondria. , 2001, Journal of molecular biology.

[16]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[17]  T. Wallimann,et al.  A conserved negatively charged cluster in the active site of creatine kinase is critical for enzymatic activity. , 2000, The Journal of biological chemistry.

[18]  A. D. Jones,et al.  Monocrotaline pyrrole targets proteins with and without cysteine residues in the cytosol and membranes of human pulmonary artery endothelial cells , 2005, Proteomics.

[19]  G. Zeevalk,et al.  Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine‐associated diseases , 2004, Journal of neurochemistry.

[20]  D. Butterfield,et al.  Redox proteomic identification of 4-Hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease , 2008, Neurobiology of Disease.

[21]  M. Zigmond,et al.  Modification of Dopamine Transporter Function: Effect of Reactive Oxygen Species and Dopamine , 1996, Journal of neurochemistry.

[22]  L. Elferink,et al.  Tyrosine Hydroxylase Is Inactivated by Catechol‐Quinones and Converted to a Redox‐Cycling Quinoprotein , 1999, Journal of neurochemistry.

[23]  R. Simantov,et al.  Mitochondrial voltage‐dependent anion channel is involved in dopamine‐induced apoptosis , 2002, Journal of neurochemistry.

[24]  T. Hirokawa,et al.  Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.

[25]  A. Torroni,et al.  Mitochondrial oxidative phosphorylation defects in parkinson's disease , 1991, Annals of neurology.

[26]  L. Bini,et al.  Selectivity of protein carbonylation in the apoptotic response to oxidative stress associated with photodynamic therapy: a cell biochemical and proteomic investigation , 2004, Cell Death and Differentiation.

[27]  S. Chakrabarti,et al.  Dopamine induced protein damage in mitochondrial-synaptosomal fraction of rat brain , 2001, Brain Research.

[28]  P. Ljubuncic,et al.  Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. , 2004, Biochemical pharmacology.

[29]  T. Veenstra,et al.  Identification of oxidized mitochondrial proteins in alcohol‐exposed human hepatoma cells and mouse liver , 2004, Proteomics.

[30]  E. J. Song,et al.  Oxidative modification of nucleoside diphosphate kinase and its identification by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2000, Biochemistry.

[31]  T. Miura,et al.  Inactivation of creatine kinase induced by dopa and dopamine in the presence of ferrylmyoglobin. , 1999, Chemico-biological interactions.

[32]  Kanefusa Kato,et al.  Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays , 1994, Journal of the Neurological Sciences.

[33]  Michael Cascio,et al.  Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine , 2008, Journal of neurochemistry.

[34]  D. Tse,et al.  Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.

[35]  I. Boldogh,et al.  Interactions of mitochondria with the actin cytoskeleton. , 2006, Biochimica et biophysica acta.

[36]  B. Knoops,et al.  Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+ , 2008, Neuroscience Letters.

[37]  B. Halliwell,et al.  Role of Free Radicals in the Neurodegenerative Diseases , 2001, Drugs & aging.

[38]  M. Zigmond,et al.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Kaul,et al.  Involvement of Mortalin in Cellular Senescence from the Perspective of its Mitochondrial Import, Chaperone, and Oxidative Stress Management Functions , 2007, Annals of the New York Academy of Sciences.

[40]  R. Luduena,et al.  Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. , 1991, Pharmacology & therapeutics.

[41]  M. Cameron Sullards,et al.  Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases* , 2006, Journal of Biological Chemistry.

[42]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[43]  S. Ito,et al.  Covalent binding of catechols to proteins through the sulphydryl group. , 1988, Biochemical pharmacology.

[44]  B. Bergamasco,et al.  Proteome analysis of human substantia nigra in Parkinson's disease , 2004, Proteomics.

[45]  Y. Kato,et al.  Effects of dopamine and L‐DOPA on survival of PC12 cells , 2000, Journal of neuroscience research.

[46]  G. Perry,et al.  Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers , 2005, Molecular and Cellular Biochemistry.

[47]  Nuzhat Ahmed,et al.  Strategies for revealing lower abundance proteins in two-dimensional protein maps. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[48]  L. Sweetlove,et al.  Enolase takes part in a macromolecular complex associated to mitochondria in yeast. , 2006, Biochimica et biophysica acta.

[49]  Rina Bandopadhyay,et al.  The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. , 2004, Brain : a journal of neurology.

[50]  Allan I. Levey,et al.  Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases* , 2004, Journal of Biological Chemistry.

[51]  M. Kikuchi,et al.  A Possible Role of ER-60 Protease in the Degradation of Misfolded Proteins in the Endoplasmic Reticulum (*) , 1995, The Journal of Biological Chemistry.

[52]  M. Kito,et al.  Catalytic cysteine residues of ER‐60 protease , 2000, FEBS letters.

[53]  Barry Halliwell,et al.  Oxidative stress and neurodegeneration: where are we now? , 2006, Journal of neurochemistry.

[54]  H. Maker,et al.  Amine-mediated toxicity The effects of dopamine, norepinephrine, 5-hydroxytryptamine, 6-hydroxydopamine, ascorbate, glutathione and peroxide on the in vitro activities of creatine and adenylate kinases in the brain of the rat , 1986, Neuropharmacology.

[55]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[56]  E. Klein,et al.  Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: relevance to dopamine pathology in schizophrenia. , 2008, Biochimica et biophysica acta.

[57]  Dennis W Wilson,et al.  Protein targets of 1,4‐benzoquinone and 1,4‐naphthoquinone in human bronchial epithelial cells , 2003, Proteomics.

[58]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[59]  R. Pietruszko,et al.  Inactivation of aldehyde dehydrogenase in intact rat liver mitochondria by dopamine. , 1989, Alcohol.

[60]  W. Strittmatter,et al.  Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice , 2007, Neurobiology of Aging.

[61]  J. T. Greenamyre,et al.  Parkinson's--Divergent Causes, Convergent Mechanisms , 2004, Science.

[62]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[63]  M. Kito,et al.  Protein degradation by the phosphoinositide-specific phospholipase C-alpha family from rat liver endoplasmic reticulum. , 1992, The Journal of biological chemistry.

[64]  D. Butterfield,et al.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. , 2002, Free radical biology & medicine.

[65]  Todd B. Sherer,et al.  Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.

[66]  Visith Thongboonkerd,et al.  Proteomic identification of nitrated proteins in Alzheimer's disease brain , 2003, Journal of neurochemistry.

[67]  Li Li,et al.  The mitochondrial inner membrane protein mitofilin controls cristae morphology. , 2005, Molecular biology of the cell.

[68]  Min Shi,et al.  Biomarker discovery in neurodegenerative diseases: A proteomic approach , 2009, Neurobiology of Disease.

[69]  I. Tarassov,et al.  A glycolytic enzyme, enolase, is recruited as a cofactor of tRNA targeting toward mitochondria in Saccharomyces cerevisiae. , 2006, Genes & development.

[70]  K. Vrana,et al.  Cytotoxic and genotoxic potential of dopamine , 1999, Journal of neuroscience research.

[71]  S. Berman,et al.  Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain Mitochondria , 1999, Journal of neurochemistry.

[72]  T. Montine,et al.  Covalent Crosslinking of Neurofilament Proteins by Oxidized Catechols as a Potential Mechanism of Lewy Body Formation , 1995, Journal of neuropathology and experimental neurology.

[73]  S. Weintraub,et al.  Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimer's disease. , 2004, Free radical biology & medicine.

[74]  A. Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.

[75]  T. Hastings,et al.  Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine , 2000, Neuroscience.

[76]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[77]  M. Beal Mitochondria and neurodegeneration. , 2007, Novartis Foundation symposium.

[78]  S. Lipton,et al.  S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[79]  M. Asanuma,et al.  L-DOPA treatment from the viewpoint of neuroprotection , 2005, Journal of Neurology.

[80]  G. Nappi,et al.  Quantitative study of mitochondrial complex I in platelets of parkinsonian patients , 1998, Movement disorders : official journal of the Movement Disorder Society.

[81]  M. Cascio,et al.  Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: Implications for Parkinson disease , 2008, Neurobiology of Disease.

[82]  Yan Wang,et al.  Proteomic Identification of a Stress Protein, Mortalin/mthsp70/GRP75 , 2006, Molecular & Cellular Proteomics.

[83]  G. Cohen,et al.  Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[84]  P. Yu,et al.  Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. , 1997, Biochemical pharmacology.

[85]  Mark A. Wilson,et al.  The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[86]  S. Jana,et al.  Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. , 2005, Biochimica et biophysica acta.

[87]  T. Hastings Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase , 1995, Journal of neurochemistry.

[88]  T. Montine,et al.  Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction , 2005, Brain Research.

[89]  I. Boldogh,et al.  Mitochondria on the move. , 2007, Trends in cell biology.

[90]  L. Ruddock,et al.  The human protein disulphide isomerase family: substrate interactions and functional properties , 2005, EMBO reports.

[91]  D. Butterfield,et al.  Protein oxidation in the brain in Alzheimer's disease , 2001, Neuroscience.

[92]  T. Hirano,et al.  Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. , 2005, The Biochemical journal.

[93]  D. Brdiczka,et al.  The function of complexes between the outer mitochondrial membrane pore (VDAC) and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis. , 2003, Acta biochimica Polonica.

[94]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[95]  Simon C Watkins,et al.  Quantitative Biochemical and Ultrastructural Comparison of Mitochondrial Permeability Transition in Isolated Brain and Liver Mitochondria: Evidence for Reduced Sensitivity of Brain Mitochondria , 2000, Experimental Neurology.

[96]  J. Borowitz,et al.  Dopamine‐Induced Apoptosis Is Mediated by Oxidative Stress and Is Enhanced by Cyanide in Differentiated PC12 Cells , 2000, Journal of neurochemistry.

[97]  D. Petersen,et al.  Residue-specific adduction of tubulin by 4-hydroxynonenal and 4-oxononenal causes cross-linking and inhibits polymerization. , 2007, Chemical research in toxicology.

[98]  M. Kito,et al.  Inhibition by acidic phospholipids of protein degradation by ER‐60 protease, a novel cysteine protease, of endoplasmic reticulum , 1992, FEBS letters.

[99]  M. Vila,et al.  The parkinsonian toxin MPTP: action and mechanism. , 2000, Restorative neurology and neuroscience.

[100]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[101]  M. Carré,et al.  Tubulin Is an Inherent Component of Mitochondrial Membranes That Interacts with the Voltage-dependent Anion Channel* , 2002, The Journal of Biological Chemistry.